Last updated: September 6, 2026
Basic Care Naproxen Sodium PM is an OTC nighttime analgesic combining naproxen sodium, an NSAID, with diphenhydramine, an antihistamine sleep aid. The principal commercial opportunity is private-label substitution for Aleve PM, not protection of a novel active ingredient. The strongest value levers are low-cost tablet manufacture, robust stability, packaging efficiency, and differentiated dosage forms that remain within FDA OTC requirements.
What is Basic Care Naproxen Sodium PM?
Basic Care Naproxen Sodium PM is generally positioned as a store-brand equivalent to nighttime naproxen products. The reference commercial concept uses:
| Component |
Typical role |
| Naproxen sodium |
Analgesic and antipyretic |
| Diphenhydramine hydrochloride |
Nighttime sleep-aid ingredient |
| Tablet excipients |
Compression, disintegration, lubrication, coating and stability |
The common reference strength for this product category is naproxen sodium 220 mg plus diphenhydramine hydrochloride 25 mg per caplet or tablet. The exact Basic Care inactive-ingredient composition should be verified against the current package label and applicable National Drug Code record before making a formulation, infringement or manufacturing decision.
Naproxen sodium is the sodium salt of naproxen and provides faster dissolution than the free acid. Diphenhydramine hydrochloride adds nighttime positioning but also creates formulation constraints because the product combines a relatively high-dose NSAID with a low-dose, moisture-sensitive antihistamine.
What FDA regulatory pathway applies to Basic Care Naproxen Sodium PM?
The product is commercially structured as an OTC drug rather than as a new prescription product. Naproxen and diphenhydramine are each recognized OTC active ingredients under FDA monograph provisions, subject to permitted indications, doses, warnings, labeling and dosage forms.
FDA status and OTC monograph position
The relevant regulatory framework includes:
- FDA’s OTC analgesic and antipyretic monograph framework for naproxen sodium.
- FDA’s OTC sleep-aid monograph framework for diphenhydramine.
- FDA labeling requirements under the Drug Facts regulation.
- OTC monograph reform provisions under the Coronavirus Aid, Relief, and Economic Security Act.
A product that conforms to the applicable monograph conditions generally does not need an individual new-drug approval. A formulation that falls outside those conditions, makes unsupported claims, or uses a novel dosage form may require an FDA-approved application.
The reference prescription-style development history is less important for Basic Care than monograph compliance. Private-label OTC products compete primarily through cost, supply reliability and retail execution.
What is the Orange Book status of Basic Care Naproxen Sodium PM?
Basic Care Naproxen Sodium PM is not expected to have a conventional Orange Book patent-exclusivity position if marketed under the OTC monograph pathway.
| Issue |
Commercial implication |
| Orange Book listing |
Usually not applicable to a monograph OTC product |
| Paragraph IV certification |
Generally not applicable without an ANDA referencing an approved NDA |
| New-drug exclusivity |
No new exclusivity for a compliant monograph product |
| Reference-product protection |
May exist for an NDA product such as Aleve PM, but does not normally create a barrier to monograph-compliant private-label products |
| Patent clearance |
Still required for formulation, process, packaging and method-of-use patents |
Aleve PM was approved as an NDA product, but the commercial protection associated with its approval does not automatically prevent a separate OTC product from relying on applicable monograph conditions. Any product-specific patent analysis requires a current search of the FDA Orange Book, USPTO records and court dockets.
When does Basic Care Naproxen Sodium PM lose exclusivity?
Basic Care does not have a conventional patent exclusivity period in the same way as an approved innovative drug. The product’s market protection is based on branding, retailer control, supply contracts, packaging, quality systems and shelf placement.
The competitive entry timeline is therefore determined by:
- Whether the product conforms to the OTC monographs.
- Whether an incumbent holds enforceable formulation or packaging patents.
- Whether a contract manufacturer can produce compliant tablets at scale.
- Whether the retailer accepts another private-label supplier.
- Whether the competing product can obtain stable supply and pass quality testing.
Generic or store-brand entry can occur without waiting for expiration of an active-ingredient patent when the drug is marketed under the OTC monograph pathway and no enforceable formulation or method patent blocks the proposed product.
What excipients are strategically important?
A practical tablet platform should prioritize direct compression or low-complexity granulation, rapid disintegration, low friability and protection from moisture.
Core excipient functions
| Formulation function |
Candidate excipient classes |
Strategic objective |
| Dilution and tablet mass |
Microcrystalline cellulose, lactose, dibasic calcium phosphate |
Achieve consistent tablet weight and compression |
| Binder |
Povidone, copovidone, pregelatinized starch |
Improve mechanical strength |
| Disintegrant |
Croscarmellose sodium, crospovidone, sodium starch glycolate |
Offset tablet density and support dissolution |
| Glidant |
Colloidal silicon dioxide |
Improve powder flow |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduce ejection force and tooling adhesion |
| Film coating |
Hypromellose, polyethylene glycol, talc, colorants |
Improve swallowability, appearance and handling |
| Moisture control |
Low-moisture excipient grades, desiccant packaging |
Protect stability and dissolution |
The excipient system should be selected around the combined behavior of naproxen sodium and diphenhydramine hydrochloride. Salt interactions, hygroscopicity, lubricant concentration and coating permeability can change dissolution and stability.
Direct compression versus wet granulation
Direct compression offers the lowest process cost and the shortest manufacturing cycle. It is attractive for a high-volume private-label product if the powder blend has adequate flow and content uniformity.
Wet granulation may improve blend uniformity and tablet strength, but it adds water, heat and processing time. Those factors increase the risk of degradation, salt migration or altered dissolution. A dry-granulation or roller-compaction process can provide a middle option where direct compression does not produce adequate tablet robustness.
Excipients with commercial differentiation potential
Most excipients in a conventional formulation will not create meaningful standalone patent value. Differentiation can arise from a defined combination or process that produces a measurable benefit, such as:
- A lower-weight caplet with equivalent dissolution.
- A coating that reduces the bitter or irritating taste of diphenhydramine.
- A low-moisture formulation with improved shelf life.
- A bilayer tablet separating naproxen sodium and diphenhydramine until dissolution.
- A rapidly disintegrating nighttime tablet.
- A smaller tablet suitable for older consumers or consumers with swallowing difficulty.
- A formulation that reduces naproxen sodium exposure to the gastric environment through delayed or enteric release.
The last category carries higher regulatory and clinical risk because changing release characteristics can affect onset, efficacy, safety and monograph conformity.
What formulation patents could protect a nighttime naproxen product?
The active ingredients themselves are mature and generally offer limited patent opportunity. New protection would more likely focus on the dosage form, manufacturing process or defined excipient ratio.
Potential claim categories
Fixed-dose combination claims
A claim directed to naproxen sodium and diphenhydramine in a defined ratio may be difficult to sustain if the combination and dosing concept are already publicly known. Patentability would depend on a non-obvious technical effect, such as an unexpected stability or dissolution advantage.
Bilayer or multilayer tablets
A bilayer tablet could separate the NSAID and antihistamine during manufacture or storage. Potential benefits include:
- Reduced chemical interaction.
- Better content uniformity.
- Independent release profiles.
- Smaller total tablet volume.
- Product differentiation from conventional caplets.
The risk is higher manufacturing cost and more demanding process validation.
Modified-release dosage forms
A delayed-release or extended-release naproxen/diphenhydramine product could support a stronger formulation patent if it provides a clinically meaningful release profile. It would also face more extensive FDA review and may not fit within the standard monograph pathway.
Coating and taste-masking technology
A film coat or functional barrier may be patentable when it uses a defined polymer system, coating weight, dissolution window or process condition. Taste masking has commercial value for chewable, orally disintegrating or liquid products, but conventional swallowed caplets have less need for it.
Manufacturing-process claims
Process claims may cover:
- A controlled dry-granulation sequence.
- A low-shear blending process.
- A defined lubricant addition time.
- A moisture-controlled coating operation.
- A method that improves content uniformity or dissolution consistency.
Process patents are often more difficult to detect through finished-product testing and may create stronger manufacturing barriers than simple excipient-composition claims.
How strong is the patent estate for Basic Care Naproxen Sodium PM?
The expected patent estate is weak for the conventional product and stronger only for a differentiated formulation.
| Patent area |
Expected strength |
Reason |
| Naproxen sodium active ingredient |
Low |
Mature NSAID salt |
| Diphenhydramine active ingredient |
Low |
Long-established OTC sleep aid |
| Conventional fixed-dose combination |
Low to moderate |
Combination concept is readily apparent |
| Standard excipient blend |
Low |
Common excipient choices are predictable |
| Novel bilayer or modified-release tablet |
Moderate to high |
Requires technical data and may support non-obviousness |
| Specialized coating or taste masking |
Moderate |
Strength depends on formulation specificity |
| Manufacturing process |
Moderate |
Stronger if process produces measurable quality advantages |
| Packaging system |
Low to moderate |
Higher value if it controls moisture and extends shelf life |
Patent strength should be measured by claim scope, written-description support, freedom-to-operate exposure and the ability to detect infringement. A broad claim covering only naproxen, diphenhydramine and ordinary tableting excipients would face substantial validity risk.
What manufacturing and IP barriers affect commercial entry?
The main barriers are operational rather than molecule-based.
Manufacturing barriers
A private-label manufacturer must control:
- Blend uniformity for two active ingredients with different dose levels.
- Tablet weight and hardness.
- Naproxen sodium dissolution.
- Diphenhydramine assay and content uniformity.
- Moisture exposure during granulation and coating.
- Lot-to-lot color and appearance.
- Packaging integrity over the labeled shelf life.
- Cross-contamination controls for potent or sensitizing materials.
- Stability under accelerated and long-term conditions.
The low-dose diphenhydramine component is the principal content-uniformity challenge. Naproxen sodium determines much of the tablet mass, while diphenhydramine must remain evenly distributed through blending and compression.
Intellectual-property barriers
A freedom-to-operate review should cover:
- U.S. patents assigned to the NDA holder or reference-product manufacturer.
- Continuation and divisional applications involving PM formulations.
- Formulation patents covering antihistamine-NSAID combinations.
- Coating, bilayer and modified-release patents.
- Packaging patents involving moisture protection or unit-dose delivery.
- Manufacturing patents held by contract manufacturers.
- Foreign patents if the product will be produced or sold outside the United States.
Which companies are positioned to compete?
The relevant competitive field includes:
- Bayer, through Aleve and Aleve PM.
- Amazon’s Basic Care private-label platform.
- Perrigo and other OTC contract manufacturers.
- Retail pharmacy brands, including CVS, Walgreens and Rite Aid.
- Mass merchants and supermarket private labels.
- Generic manufacturers with OTC naproxen sodium capabilities.
Competition is driven by retailer access and manufacturing economics. A contract manufacturer with existing naproxen, diphenhydramine and film-coating capacity can enter more quickly than a company building a dedicated line.
What commercial opportunities exist for excipient innovation?
Lower-cost standard caplet
This is the most immediate opportunity. A robust direct-compression formulation can reduce conversion cost, improve line throughput and support large retail packs. The product is unlikely to command a premium, so the main economic objective is cost reduction without compromising dissolution or shelf life.
Smaller swallowable tablet
A smaller caplet could improve consumer acceptance, particularly for older adults who already take multiple medicines. The challenge is maintaining dose capacity, mechanical strength and fast disintegration.
Unit-dose blister packaging
Blister packaging can improve portability, dose tracking and protection from humidity. It costs more than bottles but can support travel, convenience and pharmacy channels.
Two-product nighttime platform
The formulation platform could be extended to:
- Naproxen sodium plus diphenhydramine caplets.
- Lower-dose naproxen nighttime products.
- Liquid gels.
- Softgels.
- Day-and-night combination packs.
- Family or travel-size packaging.
Each extension requires separate review of dosage form suitability, labeling, stability and manufacturing capability.
Retailer-exclusive packaging
Private-label value can be increased through differentiated pack counts, club-store formats, travel packs and seasonal merchandising. These rights are commercial rather than patent-based and can be protected through supply agreements and retailer relationships.
What generic launch risks exist?
A conventional monograph-compliant competitor can likely launch without a Paragraph IV dispute. The main launch risks are:
- Failure to meet dissolution specifications.
- Inadequate content uniformity for diphenhydramine.
- Labeling errors involving drowsiness, alcohol, sedatives or NSAID warnings.
- Stability failures caused by moisture.
- Supplier dependence for active ingredients or specialized excipients.
- Retailer quality audits.
- Recalls caused by tablet defects or packaging mix-ups.
- Patent claims directed to an unrecognized coating, process or combination product.
The lowest-risk launch is a conventional immediate-release caplet using widely available excipients and a well-established bottle or blister package.
How does Basic Care compare with Aleve PM?
| Factor |
Basic Care Naproxen Sodium PM |
Aleve PM |
| Market role |
Private-label or value brand |
Branded reference product |
| Active ingredients |
Naproxen sodium plus diphenhydramine |
Naproxen sodium plus diphenhydramine |
| Primary advantage |
Price and retailer distribution |
Brand recognition and consumer trust |
| Patent value |
Limited for standard formulation |
May include product-specific formulation or NDA-related rights |
| Regulatory route |
OTC monograph-oriented |
NDA-originated commercial product |
| Excipient opportunity |
Cost, stability and manufacturability |
Brand differentiation and product lifecycle management |
| Commercial risk |
Retailer dependence and margin pressure |
Brand erosion and private-label substitution |
What is the revenue exposure from private-label competition?
The product category is exposed to substitution because consumers often view OTC nighttime analgesics as interchangeable when the active ingredients and strengths match. Private-label share can increase when:
- The branded product has a wide retail price premium.
- Retailers control search placement and shelf position.
- The private-label product matches the reference Drug Facts panel.
- The package offers a higher tablet count.
- Supply shortages affect the branded product.
- Consumers are already familiar with store-brand OTC medicines.
Revenue exposure is highest for standard immediate-release products. It is lower for differentiated delivery systems, clinically supported formulations and brands with strong loyalty.
Key Takeaways
- Basic Care Naproxen Sodium PM is primarily a private-label OTC opportunity, not a new-molecule patent opportunity.
- The likely commercial formulation combines naproxen sodium 220 mg with diphenhydramine hydrochloride 25 mg.
- The conventional product has limited patent strength because both active ingredients and the nighttime combination are mature.
- Excipient strategy should prioritize direct compression, fast disintegration, low moisture exposure and reliable content uniformity.
- The strongest potential IP areas are bilayer tablets, modified release, taste masking, moisture-control systems and specialized manufacturing processes.
- A monograph-compliant product generally avoids the conventional ANDA Paragraph IV pathway.
- Generic entry risk is high for a standard caplet and lower for a formulation with validated technical differentiation.
- Manufacturing execution, retailer economics and packaging are more important than active-ingredient exclusivity.
FAQs
Can naproxen sodium and diphenhydramine be combined in one OTC tablet?
Yes, the combination is commercially established, but the product must comply with FDA requirements governing active ingredients, dosage, indications, warnings, labeling and quality.
Is a new patent available for a standard naproxen PM caplet?
A broad patent on a conventional naproxen sodium and diphenhydramine caplet would face substantial prior-art and obviousness risk. Patent value is more likely in a specific release system, coating, process or stability solution.
Which excipient is most important for diphenhydramine content uniformity?
The most important factor is the overall blending and granulation system, not one excipient. Particle-size control, ordered mixing, low-dose premixing and validated blend uniformity are central.
Would an orally disintegrating naproxen PM tablet create a stronger commercial position?
It could create differentiation, but naproxen sodium’s dose burden, taste, tablet mass and moisture sensitivity make the dosage form technically difficult. The product may also require regulatory analysis beyond a conventional swallowed caplet.
Is blister packaging commercially preferable to a bottle?
Blisters provide better unit-dose protection and portability but usually cost more. Bottles are generally more attractive for high-volume value retail, while blisters can support travel, adherence and moisture-control positioning.
References
-
U.S. Food and Drug Administration. (2010). Drugs@FDA: Aleve PM, NDA 022476. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2023). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2023). OTC monograph M010: Sleep aid drug products for over-the-counter human use. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2020). Over-the-counter monograph reform in the CARES Act. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). DailyMed: Naproxen sodium and diphenhydramine hydrochloride drug labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Patent and Trademark Office. (2024). Patent Public Search. https://ppubs.uspto.gov/pubwebapp/♀♀♀♀♀♀
